Mergers May Buy Time, But Fundamental Change Is Necessary, GSK’s Garnier
Executive Summary
The spate of large scale mergers at the beginning of the decade provided companies with time to deal with patent expirations, but ultimately firms need to fundamentally change their business model, GlaxoSmithKline CEO J.P. Garnier said